Madrigal Pharmaceuticals (MDGL) EBIT (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of EBIT data on file, last reported at -$92.7 million in Q1 2026.

• On a quarterly basis, EBIT fell 16.91% year-over-year to -$92.7 million in Q1 2026; TTM through Mar 2026 was -$313.5 million, a 26.26% increase from a year earlier, with the FY2025 full-year figure at -$300.1 million, up 39.72% from the prior year.
• EBIT for Q1 2026 stood at -$92.7 million, down from -$59.6 million in the prior quarter.
• Over the last five years, EBIT for MDGL reached as high as -$47.2 million in Q2 2025 and fell as low as -$162.5 million in Q2 2024.
• Historically, EBIT has averaged -$92.0 million across 5 years, with a median of -$85.3 million in 2022.
• Across the five-year window, EBIT slumped 94.08% in 2024 and soared 70.96% in 2025, its largest moves.
• Year by year, EBIT stood at -$85.3 million in 2022, then tumbled by 37.37% to -$117.2 million in 2023, then surged by 42.82% to -$67.0 million in 2024, then climbed by 11.03% to -$59.6 million in 2025, then tumbled by 55.55% to -$92.7 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$92.7 million in Q1 2026, -$59.6 million in Q4 2025, and -$114.0 million in Q3 2025.